Is It Time To Reassess Veeva Systems (VEEV) After Its Prolonged Share Price Slide

• Wondering if Veeva Systems at around US$173.98 is starting to look like value, or if the recent slide is a warning sign you should pay attention to?
• The share price has seen declines of 2.4% over the last week, 6.4% over the last month, and 20.7% year to date, adding to a 21.5% fall over the past year and a 33.9% decline over five years.
• These moves have kept Veeva Systems in focus as investors reassess how much they are willing to pay for healthcare software names, with valuation and growth assumptions coming under closer scrutiny. Evergreen coverage like this aims to step back from short term headlines and focus on how the current price lines up with a range of valuation measures.
• Right now, Veeva Systems holds a valuation score of 3 out of 6. The next sections break down what that means across different valuation approaches and point to a broader way of thinking about value that comes at the end of the article.

Veeva Systems delivered -21.5% returns over the last year. See how this stacks up to the rest of the Healthcare Services industry.

Approach 1: Veeva Systems Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash Veeva Systems is expected to generate in the future and then discounts those cash flows back to today to estimate what the business might be worth now.

Veeva Systems last twelve month free cash flow is reported at about $1.39b. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates point to projected free cash flow of $2.43b in 2031, with a path of forecast and extrapolated cash flows between 2026 and 2035. Simply Wall St discounts each of those future cash flow figures to today using its chosen rate and sums them to arrive at an intrinsic value per share.

On this basis, the DCF model suggests an estimated fair value of about $268.71 per share. Compared with the recent share price of about $173.98, this implies the stock is around 35.3% below that modelled value. Under these assumptions, this points to Veeva Systems trading at a discount according to this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Veeva Systems is undervalued by 35.3%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Veeva Systems.

Approach 2: Veeva Systems Price vs Earnings

For a profitable business like Veeva Systems, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. Investors usually accept a higher or lower P/E depending on what they expect for future earnings growth and how much risk they see in the business and sector.

Veeva Systems is currently on a P/E of about 31.3x. That sits above the Healthcare Services industry average of around 28.0x and the peer group average of about 28.5x. On the surface, that suggests the market is assigning a higher price tag to Veeva Systems earnings than to many peers in its space.

Simply Wall St’s Fair Ratio for Veeva Systems comes in at roughly 29.0x. This is a proprietary estimate of what a “normal” P/E could look like for the company, based on factors such as its earnings growth profile, profit margins, industry, market cap and company specific risks. Because it adjusts for these company level characteristics, the Fair Ratio can often be more informative than simple comparisons with the industry or peer averages.

With a current P/E of 31.3x versus a Fair Ratio of 29.0x, Veeva Systems screens as trading above that Fair Ratio benchmark.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Veeva Systems Narrative

Earlier it was mentioned that there is an even better way to think about valuation. Narratives on Simply Wall St let you attach your story about Veeva Systems to the numbers by linking your views on its future revenue, earnings and margins to a forecast and a fair value, then comparing that fair value with the current price to see whether your story points you toward buying, holding or selling. The whole view updates as fresh news or earnings arrive. For example, one investor might build a bullish Veeva Narrative around AI agents, Development Cloud expansion and a higher end fair value that lines up with targets around US$350 to US$380. Another might build a cautious Narrative that leans closer to the lower end of the analyst range around US$190 to US$215 if they are more focused on competition, CRM churn and slower product adoption.

Do you think there's more to the story for Veeva Systems? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com